SPMs (Specialized Pro-resolving Mediators) are endogenous lipid mediators synthesized from omega-3 fatty acids (EPA, DHA) and omega-6 fatty acids that actively orchestrate resolution of inflammation rather than passively suppress it. Four main families exist: lipoxins (from arachidonic acid), E-series resolvins (from EPA), D-series resolvins (from DHA), and protectins/maresins (from DHA). These molecules represent a paradigm shift: inflammation resolution is not the absence of inflammatory signals but the presence of specific resolution signals acting in picomolar-to-nanomolar concentrations—1000× more potent than prostaglandins.
Think of acute inflammation as a construction site that's been demolished to clear damaged tissue. The wrecking crew (neutrophils, prostaglandinE2, TNF-α) tears everything down—this is necessary, not pathological. But imagine if the wrecking crew never left and no cleanup crew arrived. The site would remain rubble forever (= chronic inflammation).
SPMs are the foreman's whistle that calls off the wrecking crew and summons the cleanup team. When the foreman (activated COX-2) switches from demolition mode to resolution mode, they stop making wrecking orders (prostaglandins) and start making cleanup orders (SPMs). The cleanup crew (M2 macrophages) arrives, picks up debris (efferocytosis of dead cells), rebuilds tissue, and leaves the site better than before. The foreman's whistle (SPMs) works at incredibly low volume—just a few molecules can redirect an entire crew of thousands.
Critically: you cannot have cleanup without demolition first. Taking NSAIDs early is like firing the foreman before they can blow the whistle—you get stuck rubble with no one to clear it.
SPM synthesis occurs through enzymatic conversion of polyunsaturated fatty acids via lipoxygenase (LOX) and cyclooxygenase (COX-2) pathways:
1. Lipoxin Synthesis (from arachidonic acid):
2. E-series Resolvin Synthesis (from EPA):
- 5-LOX converts EPA → 5-HEPE
- Further conversion → resolvin E1 (RvE1), RvE2, RvE3
- Aspirin-triggered: AT-RvE1, AT-RvE2
3. D-series Resolvin Synthesis (from DHA):
4. Protectin Synthesis (from DHA):
- 15-LOX pathway → protectin D1 (PD1, also called neuroprotectin D1 in brain)
- Aspirin-triggered: AT-PD1
5. Maresin Synthesis (from DHA):
graph TD
AA[Arachidonic Acid] -->|15-LOX| 15HETE[15-HETE]
15HETE -->|5-LOX| LXA4[Lipoxin A4/B4]
EPA[EPA] -->|5-LOX| 5HEPE[5-HEPE]
5HEPE --> RvE[Resolvin E1/E2/E3]
DHA[DHA] -->|15-LOX| 17HpDHA[17-HpDHA]
17HpDHA --> RvD[Resolvin D1-D6]
DHA -->|15-LOX pathway| PD1[Protectin D1]
DHA -->|12-LOX| 14HpDHA[14-HpDHA]
14HpDHA --> MaR[Maresin 1/2]
COX2["COX-2 + Aspirin"] --> ASPM[Aspirin-triggered SPMs]
style AA fill:#ffe6e6
style EPA fill:#e6f3ff
style DHA fill:#e6f3ff
style ASPM fill:#fff9e6
The eicosanoid class switch marks the transition from inflammation to resolution:
- Early inflammation (0-12 hours): COX-2 produces prostaglandinE2 (PGE2), prostaglandinD2, thromboxane → vasodilation, pain, neutrophil recruitment
- Switch trigger (12-24 hours): COX-2 becomes acetylated (by aspirin) or S-nitrosylated (by NO)
- Post-switch (24-72 hours): Modified COX-2 now produces lipoxins and aspirin-triggered resolvins instead of prostaglandins
- This represents substrate/product switching without changing enzyme levels—same enzyme, different output
¶ Receptor Signaling and Cellular Actions
SPMs bind specific G-protein coupled receptors triggering resolution cascades:
Receptor Binding:
Downstream Signaling (example: RvD1 → GPR32):
RvD1 binding GPR32 → Gαi protein activation → ↓cAMP → ↓PKA → ↓NF-κB nuclear translocation → ↓pro-inflammatory gene transcription (TNF-α, IL-6, IL-1β)
Simultaneously: RvD1 → GPR32 → PI3K/Akt activation → enhanced phagocytosis and efferocytosis
Cellular Effects:
-
Neutrophils:
- Stop chemotaxis (40-70% reduction in tissue infiltration)
- Promote apoptosis instead of necrosis (prevents secondary damage)
- Reduce reactive oxygen species production
- Active concentration: 1-10 nM
-
Macrophages:
- Shift M1 (pro-inflammatory) → M2 (pro-resolution) phenotype
- Enhance efferocytosis (clearance of apoptotic neutrophils) by 2-3×
- Increase IL-10 production (anti-inflammatory)
- Reduce TNF-α, IL-6, IL-1β secretion by 50-80%
- Active concentration: 0.1-1 nM
-
Tissue Repair:
- Stimulate fibroblast migration and collagen synthesis
- Promote angiogenesis via VEGF upregulation
- Enhance epithelial barrier integrity
- Reduce fibrosis by limiting excess collagen deposition
SPMs are rapidly metabolized to limit resolution phase duration:
- Oxidation: 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inactivates lipoxins
- Epimerization: Converts bioactive SPMs to inactive epimers
- β-oxidation: Shortens carbon chain, reducing receptor affinity
- Half-life in vivo: 2-15 minutes (extremely short-lived signals)
Clinical implication: Chronic low SPM levels may reflect excessive metabolic inactivation, not just insufficient synthesis.
The SPM framework fundamentally redefines chronic disease pathophysiology. Traditional medicine views chronic inflammation as too much inflammation requiring suppression (NSAIDs, corticosteroids). cPNI recognizes many chronic states as failed resolution—insufficient SPM production or excessive inactivation despite normal or even low inflammatory markers.
Clinical translation:
- Patient presents with chronic pain, elevated CRP 8 mg/L, prescribed NSAIDs
- Problem: NSAIDs block COX-2, preventing both prostaglandin production AND subsequent SPM synthesis during the eicosanoid class switch
- Result: Acute pain reduces, but resolution cascade never initiates → tissue remains in inflammatory debris state → chronic pain persists or worsens long-term
5 plus 2 metamodel integration:
- Immune dysregulation: SPM deficiency is a selfish immune system failing to complete its job
- Metabolic dysfunction: Insulin resistance impairs 15-LOX and 5-LOX activity, reducing SPM synthesis
- Chronic stress: Sustained cortisol elevates 15-PGDH (SPM-degrading enzyme), accelerating inactivation
- gut dysfunction: Dysbiosis reduces bacterial production of SPM pathway precursors
- Evolutionary mismatch: Modern omega-6:omega-3 ratios (15:1 vs. ancestral 1:1-4:1) starve SPM synthesis
Selfish immune system: When the immune system prioritizes immediate threat response over long-term tissue health, it maintains inflammatory states that benefit pathogen clearance but damage host tissue. SPMs represent the mechanism by which the organism reasserts control—telling the immune system "job done, stand down."
High clinical relevance for:
1. Omega-3 Supplementation:
- Standard anti-inflammatory dose: EPA 1-2g, DHA 1-2g daily
- Neuropathic pain resolution dose: DHA 6g daily (provides substrate saturation for D-series resolvins and protectins)
- Requires 8-12 weeks to shift tissue fatty acid composition and SPM production
- omega-3 index target: >8% (red blood cell EPA+DHA percentage)
2. Timing Considerations:
- Acute injury: NO omega-3 supplementation first 7 days—allow full inflammatory phase for proper eicosanoid class switch
- Days 7-14: Begin omega-3 to support resolution phase
- Chronic conditions: Continuous omega-3 to address baseline deficiency
3. Aspirin Paradox:
- Low-dose aspirin (81mg) uniquely promotes SPM synthesis by acetylating COX-2 → aspirin-triggered SPMs
- Higher doses block COX-2 entirely → no SPM synthesis
- Clinical use: 81mg aspirin may support resolution in chronic inflammatory states
4. Avoid Early Anti-inflammatory Suppression:
- NSAIDs, corticosteroids in first 48-72 hours block necessary inflammatory phase
- Prevents eicosanoid class switch from occurring
- Exception: Life-threatening inflammation (sepsis, anaphylaxis) where immediate suppression is necessary
5. Support Endogenous Synthesis:
- SPM plasma levels (research reference): LXA4 10-100 pg/mL, RvD1 5-50 pg/mL, RvE1 1-20 pg/mL
- Omega-3 index: <4% high risk, 4-8% intermediate, >8% optimal for SPM synthesis
- omega-6 to omega-3 ratio: Target <4:1 (modern Western diets often 15:1-20:1)
- Active concentration in tissue: Picomolar (10⁻¹² M) to nanomolar (10⁻⁹ M)—1000× more potent than prostaglandins requiring micromolar concentrations
Emerging therapeutic approach: administer synthetic SPM analogs directly
- Four SPM families: lipoxins (arachidonic acid), E-resolvins (EPA), D-resolvins (DHA), protectins/maresins (DHA)
- Active at picomolar-nanomolar concentrations (10⁻¹²-10⁻⁹ M)—1000× more potent than prostaglandins
- DHA 6g/day required for therapeutic SPM levels in neuropathic pain (far exceeds standard 1-2g anti-inflammatory doses)
- Eicosanoid class switch occurs 12-24 hours post-injury when COX-2 switches from prostaglandin to SPM synthesis
- SPMs reduce neutrophil infiltration by 40-70% and double macrophage efferocytosis rates
- Low-dose aspirin (81mg) acetylates COX-2 creating aspirin-triggered SPMs (AT-LXA4, AT-RvD1), higher doses block enzyme entirely
- Half-life in vivo: 2-15 minutes due to rapid enzymatic degradation by 15-PGDH and β-oxidation
- Resolution failure, not excessive inflammation, underlies most chronic inflammatory diseases
- NSAIDs and corticosteroids block COX-2, preventing SPM synthesis and prolonging resolution deficit
- Optimal omega-3 index for SPM synthesis: >8% (red blood cell EPA+DHA percentage)
- Modern omega-6 to omega-3 ratio (15-20:1) starves SPM pathways compared to ancestral ratios (1-4:1)
- SPM receptors: ALX-FPR2 (lipoxins, RvD1), ChemR23 (RvE1), GPR32 (RvD1-D5), GPR18 (RvD2), GPR37 (MaR1)
- specialized pro-resolving mediators — SPMs is the abbreviated term for specialized pro-resolving mediators
- resolution of inflammation — SPMs are the primary active mediators terminating inflammation and initiating tissue repair
- omega-3 fatty acids — Essential precursors for E-series and D-series resolvins, protectins, and maresins
- DHA — Docosahexaenoic acid produces D-series resolvins, protectins, and maresins via 15-LOX and 12-LOX pathways
- EPA — Eicosapentaenoic acid produces E-series resolvins via 5-LOX pathway
- resolvins — Major SPM family divided into E-series (from EPA) and D-series (from DHA)
- lipoxins — Arachidonic acid-derived SPMs marking early resolution phase
- protectins — DHA-derived SPMs with neuroprotective functions (neuroprotectin D1 in brain)
- maresins — DHA-derived SPMs synthesized by macrophages during resolution, enhance efferocytosis
- eicosanoid class switch — Critical transition where COX-2 switches from prostaglandin to SPM synthesis 12-24h post-injury
- COX-2 — Produces SPMs when acetylated (aspirin) or S-nitrosylated (NO), prostaglandins when unmodified
- aspirin — Low-dose (81mg) acetylates COX-2 enabling aspirin-triggered SPM synthesis, high doses block enzyme
- acute inflammation — Necessary precursor phase for SPM generation—early suppression prevents resolution cascade
- chronic inflammation — Reflects SPM synthesis deficiency, excessive inactivation, or receptor resistance, not just excessive inflammation
- NSAIDs — Block COX-2 impairing both prostaglandin AND subsequent SPM synthesis, worsening resolution deficit
- macrophages — SPMs shift M1→M2 phenotype, enhance efferocytosis 2-3×, reduce pro-inflammatory cytokine secretion 50-80%
- neutrophils — SPMs stop chemotaxis (40-70% reduction), promote apoptosis over necrosis, reduce ROS production
- efferocytosis — SPM-enhanced macrophage clearance of apoptotic cells, essential for resolution completion
- chronic pain — Often reflects SPM deficiency allowing inflammatory debris to persist and sensitize nociceptors
- wound healing — SPMs promote fibroblast migration, collagen synthesis, angiogenesis, epithelial barrier restoration
- 15-LOX — Key enzyme converting DHA to 17-HpDHA (resolvin precursor) and protectins, impaired by insulin resistance
- 5-LOX — Converts EPA to 5-HEPE (E-resolvin precursor) and arachidonic acid to lipoxin intermediates
- 12-LOX — Converts DHA to 14-HpDHA (maresin precursor), primarily in macrophages
- IL-6 — Pro-inflammatory cytokine reduced 50-80% by SPM signaling through GPR32/ALX-FPR2 pathways
- TNF-α — Pro-inflammatory cytokine suppressed by SPM-mediated NF-κB inhibition
- IL-10 — Anti-inflammatory cytokine upregulated by SPM-driven M2 macrophage polarization
- arachidonic acid — Omega-6 fatty acid producing lipoxins via 15-LOX and 5-LOX pathways
- insulin resistance — Impairs 15-LOX and 5-LOX enzyme activity, reducing SPM synthesis capacity
- cortisol — Chronic elevation increases 15-PGDH enzyme degrading SPMs, accelerating inactivation
- omega-6 to omega-3 ratio — Modern ratios (15-20:1) starve SPM synthesis compared to ancestral (1-4:1), evolutionary mismatch
- gut dysbiosis — Reduces bacterial production of omega-3 conversion intermediates and SCFAs supporting SPM pathways
- metabolic syndrome — Chronic low-grade inflammation (metaflammation) reflects resolution deficit, not just excess inflammation
- rheumatoid arthritis — Autoimmune condition with documented SPM deficiency in synovial fluid enabling persistent joint inflammation
- inflammatory bowel disease — Mucosal SPM levels inversely correlate with disease activity, resolution failure allows chronic gut inflammation
- neuropathic pain — DHA 6g/day therapeutic dose provides substrate for neuroprotectin D1 and D-series resolvins reducing nerve sensitization
- fibromyalgia — Centralized pain syndrome potentially reflecting systemic SPM deficiency and failed resolution signaling
- depression — Inflammatory depression subtype may require SPM pathway support rather than conventional anti-inflammatory suppression
- Type 2 diabetes — Adipose tissue inflammation reflects SPM synthesis impairment and resolution failure
- obesity — Adipocyte hypertrophy triggers inflammation, but obesity persistence reflects failed adipose tissue resolution
- NAFLD — Hepatic inflammation progressing to fibrosis when SPM-mediated resolution fails
- periodontal disease — Local SPM deficiency enables chronic gingival inflammation, RvE1 trials show promise
- asthma — Airway inflammation resolution failure, SPMs reduce eosinophil infiltration and promote airway remodeling
- multiple sclerosis — Demyelinating inflammation potentially reflecting CNS SPM deficiency and failed glial resolution
- 5 plus 2 metamodel — SPM deficiency connects immune dysregulation, metabolic dysfunction, chronic stress, gut dysfunction, and evolutionary mismatch
- selfish immune system — SPMs represent host mechanism to override selfish immune persistence and restore tissue homeostasis